Business UpdateApr 22, 2026, 04:17 PM
Silo Pharma Launches AI Subsidiary, Targets $50B Market by 2030
AI Summary
Silo Pharma, Inc. announced a strategic expansion into AI technology, establishing a new subsidiary to operate its recently acquired Qwikagents.ai platform. This move aims to create new revenue streams by leveraging the rapidly growing AI agent market, which is projected to reach $47-$53 billion by 2030 with 43-50% annual growth. The company emphasized its continued commitment to advancing its PTSD program (SPC-15) towards Phase 1 clinical trials, alongside this new AI venture.
Key Highlights
- Launched new AI subsidiary with Qwikagents.ai assets.
- Targets AI agent market, projected to reach $47-$53 billion by 2030.
- Market expected to grow 43-50% annually.
- Continues advancing PTSD program (SPC-15) to Phase 1 trials.